Efficacy and Safety of Apixaban for Pediatric Patients Requiring Anticoagulation for Treatment of Venous Thromboembolism
Driscoll J, O'Brien S, Newburger J, Mitchell L, Holzhauer S, Ahuja S, Rubio A, Gaitonde P, Robertson A, Polinsky M, Masiukiewicz U, Brandao L. Efficacy and Safety of Apixaban for Pediatric Patients Requiring Anticoagulation for Treatment of Venous Thromboembolism. Blood 2024, 144: 295-295. DOI: 10.1182/blood-2024-198612.Peer-Reviewed Original ResearchDeep vein thrombosisStandard of careLow-molecular-weight heparinVitamin K antagonistsStandard of care groupPulmonary embolismAdverse eventsApixaban groupApixaban concentrationsBleeding eventsPediatric patientsSafety profileIncidence of treatment-emergent adverse eventsLow risk of VTE recurrenceUnfractionated heparinTreatment-emergent adverse eventsRisk of VTE recurrenceStandard of care therapyAge groupsTreatment of venous thromboembolismVTE-related deathSafety of apixabanRecurrent VTE eventsTreatment of VTEMinor bleeding events